Ascentage Pharma to Attend 3 Investor Conferences in December
Ticker: AAPG · Form: 6-K · Filed: Nov 19, 2025 · CIK: 2023311
Sentiment: neutral
Topics: investor-relations, conference-participation, press-release
TL;DR
Ascentage Pharma is hitting up 3 investor conferences in Dec - expect news flow.
AI Summary
Ascentage Pharma Group International announced on November 19, 2025, that it will participate in three investor conferences in December 2025. The company, located at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China, is a pharmaceutical preparations company.
Why It Matters
Participation in investor conferences allows Ascentage Pharma to engage with potential investors and communicate its business progress and strategy, potentially influencing its stock valuation.
Risk Assessment
Risk Level: low — This filing is a routine announcement of conference participation and does not contain material financial or operational changes.
Key Players & Entities
- Ascentage Pharma Group International (company) — Filer and subject of the announcement
- November 19, 2025 (date) — Date of the press release and filing
- December 2025 (date) — Month of the upcoming investor conferences
- 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China (location) — Principal executive offices of Ascentage Pharma
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report a press release issued by Ascentage Pharma Group International on November 19, 2025, announcing its participation in three upcoming investor conferences in December 2025.
Which investor conferences will Ascentage Pharma participate in?
The filing states that Ascentage Pharma will participate in three upcoming investor conferences in December 2025, but does not specify the names of these conferences.
When was the press release announcing the conference participation issued?
The press release was issued on November 19, 2025.
Where are Ascentage Pharma Group International's principal executive offices located?
Ascentage Pharma Group International's principal executive offices are located at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China.
Does Ascentage Pharma file annual reports under Form 20-F or Form 40-F?
Ascentage Pharma indicates it files annual reports under Form 20-F.
Filing Stats: 199 words · 1 min read · ~1 pages · Grade level 14.1 · Accepted 2025-11-19 08:30:10
Filing Documents
- ea0266356-6k_ascentage.htm (6-K) — 11KB
- ea026635601ex99-1_ascentage.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 11KB
- 0001213900-25-112362.txt ( ) — 45KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2025 Commission File Number: 001-42484 ASCENTAGE PHARMA GROUP INTERNATIONAL (Translation of Registrant’s name into English) 68 Xinqing Road Suzhou Industrial Park Suzhou, Jiangsu China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE On November 19, 2025, Ascentage Pharma Group International issued a press release entitled “Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025”. A copy of the press release is furnished as Exhibit 99.1 to this Report. 1 INDEX TO EXHIBITS Exhibit Number Exhibit Title 99.1 Press Release dated November 19, 2025 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ASCENTAGE PHARMA GROUP INTERNATIONAL Date: November 19, 2025 /s/ Dajun Yang Name: Dajun Yang Title: Chief Executive Officer 3